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Background: Metaplastic breast carcinoma is a rare entity of breast cancer expressing epithelial and/or mesenchymal
tissue within the same tumor. The aim of this study is to evaluate the clinicopathological features of metaplastic breast
carcinoma and to confirm the triple negative, basal-like and/or luminal phenotype of this type of tumor by using
immunohistochemical staining.
Methods: Seven cases of MBC were evaluated for clinico-pathological features including follow up data. Cases were
studied immunohistochemically by CK-Pan, Vimentin, ER, PR, HER2, basal markers (CK5/6, p63, EGFR, SMA and S-100),
luminal cytokeratins (CK8, CK18 and CK19), markers for syncytial cells (β-HCG and PLAP), as well as prognostic markers
(p53, ki-67 and calretinin).
Results: The mean age of the patients was 36 years. Three cases showed choriocarcinomatous features. All of our
cases were negative for ER, PR and HER2. Six out of the 7 cases showed basal-like differentiation by demonstrating
positivity with at least one of the basal/myoepithelial markers. Also 6 out of the 7 cases expressed luminal type
cytokeratins (CK8, CK18 and/or CK19). P53 was positive in 3 cases, ki-67 was strongly expressed in only one case,
while calretinin was expressed in 6 cases.
Conclusion: Metaplastic breast carcinoma presents in our population at a younger age group than other international
studies. All cases are categorized immunohistochemically under the triple negative group of breast cancer and 86% of
them exhibited basal-like and luminal phenotype. Majority of cases developed local recurrence and distant metastasis
in a relatively short period of time.
Virtual Slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1101289295115804
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Metaplastic breast carcinoma (MBC) is a rare heteroge-
neous group of primary breast malignancies accounting
for less than 1% of all invasive mammary carcinomas
[1]. They are characterized by the co-existence of car-
cinoma with non-epithelial cellular elements. Recently,
the WHO working group on breast tumors adopted a
descriptive classification of MBC which includes low grade
adenosquamous carcinoma, fibromatosis-like metaplastic* Correspondence: fjaltaf@yahoo.com
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unless otherwise stated.carcinoma, spindle cell carcinoma, metaplastic carcinoma
with mesenchymal differentiation and mixed metaplastic
carcinoma [1]. MBCs usually are high-grade neoplasms
that present with a large size mass, most of them arising
de-novo, but there are reported cases that arose from pre-
existing lesions as complex sclerosing lesions, papillomas
and nipple adenomas [2,3]. Patients with MBC generally
have poorer outcome when compared with high-grade
invasive ductal carcinoma and they rarely benefit from
conventional chemotherapy or hormonal therapy [4,5].
Perou et al. demonstrated that phenotypic diversity of
breast cancer is associated with corresponding gene
expression diversity [6]. Evidence from gene expression
microarrays suggested the presence of multiple moleculard. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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like and HER2 positive [7]. These subtypes are associated
with differences in risk factors, biological behavior, clinical
outcome, histologic grades and response to therapy.
Therefore an extra effort should be spent to classify breast
cancer cases into these groups during the routine surgical
pathology workup. Hicks et al. proposed an immu-
nohistochemical panel to be used as a surrogate for
molecular classification including; estrogen receptor (ER),
progesterone receptor (PR), human epidermal growth
factor receptor-2 (HER2), epidermal growth factor receptor
(EGFR) and cytokeratin 5/6 (CK 5/6) [8]. It was widely
accepted for use in identifying breast carcinomas with
basal-like immunophenotype as defined by c-DNA micro-
arrays and may help in categorizing MBC under one of
these subtypes [7,8]. We conducted this study to evaluate
the clinicopathological features of metaplastic breast
carcinoma and to confirm the basal-like and/or luminal
phenotype of this type of tumor by using immunohisto-
chemical study.
Methods
The material of this study constitutes 7 MBC cases
collected from the archives of Anatomical Pathology
Laboratory of King Abdulaziz University Hospital
from the period of January 2005 till December 2011.
The hematoxylin and eosin (H&E) stained slides and
the reports of each case were retrieved and revaluated
by two pathologists. The clinical data were also collected
from the patients’ medical records after obtaining all
the relevant ethical approvals. The following clinico-
pathological features were assessed; age, clinical presen-
tation, tumor site, radiological features, gross features
including size, histological components, presence of in
situ ductal component, grading of the epithelial component
using Nottingham’s grading system [9], lymph node status
and presence of distant metastasis, along with follow-up
data including recurrence status and disease-free interval.
Immunohistochemical procedures
Four-μm tissue sections were cut from the paraffin blocks
(containing both tumor and benign tissue), mounted on
charged poly-L-lysine-coated slides and subjected to
immunohistochemical (IHC) procedure using polymer-
based biotin-free detection system. Cases were stained
using an automatic immunostainer (Ventana Bench Mark
XT, Ventana Inc., Tucson, AZ) following manufacturer
kits’ instruction manual. The antibodies used were the
monoclonal mouse Anti-human ER (Novocastra, 1:50),
PR (Novocastra, 1:100), HER2 neu (4B5, Ventana, Ventana
Inc., Tucson, AZ, pre-diluted), basal/myoepithelial
markers; CK5/6 (Dako Cytomation, Norden A/S, Glostrup,
Denmark, dilutions 1:25), p63 (Novocastra, 1:50), EGFR
and SMA (Dako Cytomation, Norden A/S, Glostrup,Denmark, dilution 1:200, 1:50 respectively), luminal cyto-
keratins; CK8, CK18, CK19 (Dako Cytomation, Norden
A/S, Glostrup, Denmark, dilutions 1:50, 1:50 and 1:50
respectively), and polyclonal rabbit antibody against
S100 (Dako Cytomation, Norden A/S, Glostrup, Denmark,
dilutions 1:400) and prognostic markers; p53, Ki-67 (MIB1)
and calretinin, (Dako Cytomation, Norden A/S, Glostrup,
Denmark, 1:50, 1:100 and 1:100 respectively), as well as
Pan-CK and Vimentin (Dako Cytomation, Norden A/S,
Glostrup, Denmark, dilutions 1:100 and 1:10 respectively).
PLAP (Dako Cytomation, Norden A/S, Glostrup, Denmark,
1:50) and β-HCG (Dako Cytomation, Norden A/S, Glostrup,
Denmark, 1:300) were used whenever needed.
In each analysis, positive and negative controls were
available. HER2 positivity was defined as strong complete
membranous staining (3+) in 30% or more of invasive
tumor cells according to latest ASCO-CAP guidelines
[10]. ER, PR, P63, ki67 and P53 expression was interpreted
as positive if it shows strong nuclear staining in at least
10% of the tumor cells. Moderate to strong cytoplasmic
staining of more than 10% of tumor cells for Vimentin,
Pan-CK, CK8, CK18, CK19 and CK5/6, SMA, S-100,
EGFR, calretinin, HCG and PLAP was considered positive.
The tumor is considered basal-like if it shows a triple
negative immunoprofile (for ER, PR & HER2) along with
positivity for CK5/6 and/or EGFR according to Gazinska
criteria [11].
Results
The clinicopathological features of our metaplastic car-
cinoma cases are summarized in Table 1.
Clinical features
The mean age of the patients was 36 years with a range
of 23 to 69 years. The main presenting symptom was a
breast mass, in three of the cases, the mass was fungating
and ulcerating. One case presented; in addition; with
inflammatory breast symptoms (case 6). Two cases were
discovered during pregnancy (cases 1 & 2) and a third was
discovered one year after abortion (case 3). The right
breast was involved in 6 out of the 7 cases. Radiological
examination for breast masses using ultrasound/mammo-
gram with or without MRI was performed for all cases
and revealed heterogeneous, hypo-echoic masses with
irregular outlines in the majority of them. However,
two cases exhibited well-defined borders (case 1 & 2).
The median size of the tumor was 7 cm with a range of
5 to 13 cm.
Five patients were treated by lumpectomy followed by
mastectomy. One patient was treated by modified radical
mastectomy from the beginning (case 3), and one patient
was given neoadjuvant radiotherapy followed by mastec-
tomy (case 6). Adjuvant chemotherapy was given for 5
patients. Axillary dissection was performed in 4 of the
Table 1 Clinicopathological features of metaplastic carcinoma cases




Additional features LN status Mets Recurrence Specific
feature
1 31 RT Unifocal IDC-GIII Spindle cell sarcoma Syncytiotroph
giant Cells
3/22 liver + Pregnancy
2 23 RT Unifocal IDC-GII MFH-like sarcoma Syncytiotroph
giant Cells
11/21 lung + Pregnancy
3 29 RT Unifocal DCIS Spindle cell Sarcoma Syncytiotroph
giant Cells
None None None Post abortion
4 30 RT Unifocal S C C with glandular
differentiation
None None 1/12 None Residual tumor None
5 32 RT Unifocal S C C Spindle cell Sarcoma None 1/5 None Lost case None
6 69 RT Multifocal S C C None None None None + None
7 38 LT Unifocal IDC-GIII Sarcoma heterologous chondroid
and myxoid elements
None None + None
RT = right LT = left IDC = invasive ductal carcinoma DCIS = ductal carcinoma in situ SCC = Squamous cell carcinoma LN = Lymph node ,MFH =Malignant
fibrous histiocytoma.
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oped in 4 patients while distant metastasis was seen in
2 patients. The recurrence period ranged from 4 to
34 months. Three patients were alive on regular follow-
up while we lost the follow-up for the rest of the
patients.Pathological findings
All cases were unifocal, except for one multifocal case.
Five cases had poorly circumscribed margins and firm to
hard consistency with focal friable necrotic areas. The
other two cases were well-demarcated and lobulated.
Histological examination revealed three cases to contain
malignant invasive ductal carcinoma; histological grade II
(one case) to III (2 cases) admixed with high-grade spindle
sarcomatoid elements (cases 1, 2 and 7) (Figure 1-A). Two
of these cases showed scattered multinucleated syncytio-
trophoblast-like giant cells (Figure 1-B) and one showed a
mixture of heterologous myxoid and chondroid elements
(cases 1 & 2).
Another three cases were composed of malignant
squamous component that were pure (case 6), mixed
with glandular elements (case 4) and mixed with
malignant fibrous histiocytoma (MFH)-like high-grade
sarcoma (case 5) (Figure 2).
The last case was composed of ductal carcinoma in
situ mixed with high grade spindle sarcomatoid elements
and multinucleated syncytiotrophoblast-like giant cells
(case 3).Figure 1 MBC with Choriocarcinomatous differentiation. A; MBC
showing malignant epithelial cells arranged in solid sheets surrounded
by atypical spindle cell stroma. (H&E, 40X). B; Multinucleated
synctiotrophoblasts-like giant cells scattered among high grade
malignant cells, (H&E, 100X).Immunohistochemical study results
All of the 7 cases were positive for Pan-cytokeratin, mainly
in the epithelial component (Figure 3A) and all were
positive for Vimentin in the mesenchymal component
(Figure 3B).
Figure 2 MBC –Carcinosarcoma type: CASE 5 - the epithelial
component consists of moderately differentiated SCC and the
mesenchymal component is a high grade sarcoma (H&E, 40X).
Figure 3 Pan-cytokeratin and Vimentin immunohistochemical
stain. A; Pan-cytokeratin antibody is positive in the epithelial cells
and negative in the high grade sarcoma component. (DAB, 100X).
B; Vimentin antibody is positive in the mesenchymal component
and negative in the epithelial component. (DAB, 400X).
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receptors and did not show HER2 over-expression by
immunohistochemistry (Table 2).
For basal/myoepithelial markers; six out of the seven
cases were positive to at least one of the markers
(Table 3). Positivity was as follows; CK5/6 in 4 cases
(56%) (Figure 4A, B), epidermal growth factor receptor
(EGFR) in 5 cases (71%) (Figure 5A and B), P63 in 2
cases (29%), smooth muscle actin (SMA) in 2 cases
(29%) in the malignant mesenchymal component and
only one case showed positivity for S-100.
Regarding luminal cytokeratin (Table 4), CK8 was
positive in the epithelial component of 4 cases (56%). Six
cases (86%) were positive for CK19 (Figure 6-A and B)
while only 3 cases (43%) showed reactivity to CK18
(Figure 7).
Three cases were positive for p53. Ki-67 proliferation
index was less than 5% in all of the cases expect in one
case which showed a proliferative index of 30%. Five
cases showed positive immunoreactivity to calretinin; 3
in squamous component and 2 in glandular component
(Figure 8). Mesenchymal and syncytial components were
negative for calretinin.
The three cases that contained the scattered multinu-
cleated cells showed positivity for β-HCG and PLAP in
these cells (Figures 9 and 10) (Table 5).
Discussion
Pathological classification of MBC and its differential diag-
nosis is challenging due to the diversity of the histological
patterns, rarity of the diagnosis and lack of consensus
on the most appropriate classification for this group of
tumors [1]. The actual pathogenesis of MBC is unknown
but there are some theories to clarify the morphological
diversity of this tumor, including genetic and non-genetic
mechanisms. Some reports suggested an origin from
cancer stem cells or origin from myoepithelial cells or
myoepihelial progenitors [12].
Other report adopted the theory of transformation of
the carcinomatous component into the sarcomatous
component through epithelial to mesenchymal transition
(EMT) [13]. This theory is supported by the overexpres-




1 2 3 4 5 6 7
Vimentin + + + + + + +
Pan-CK + + + + + + +
ER - - - - - - -
PR - - - - - - -
HER2neu - - - - - - -




1 2 3 4 5 6 7
CK5/6 + - - + + + -
EGFR + + + + - + -
P63 - - - - + + -
SMA + - + - - - -
S-100 + - - - - - -
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transforming growth factor-B (TGF-B) along with down
regulation of E-cadherin [13]. Demonstration of down
regulation of this molecule is demonstrated by immu-
nohistochemistry. Loss of E-cadherin is a very useful
stain in the classification of breast carcinomas in situ
with mixed pattern as well as it is useful in differentiating
lobular from ductal carcinoma [14].Figure 4 CK5/6 Immunohistochemical stain. A and B: The epithelial
components of these two cases (4 and 6) are positive for CK5/6 (DAB,
100X and 200X).
Figure 5 EGFR Immunohistochemical stain. A and B: EGFR
positivity of tumor cells, both the epithelial and the mesenchymal
component (DAB, 400 X and 200 X).Recently, the contribution of microRNAs to breast
cancer evolution and progression had been suggested
[15]. Reduction in level of miR-200f, which is an import-
ant modulator of EMT, was found which further sup-
ports the association between MBC and EMT [15,16]. In
the support of the hypothesis of the origin from stem
cell are high CD44/CD24 and CD29/CD24 ratios in
MBC, consistent with a high level of stem cell-like cells




1 2 3 4 5 6 7
CK18 + - + + - - -
CK8 + + + + - - -
CK19 + + + + + + -
Figure 6 CK19 immunohistochemical stain in MBC. A; CK19 strong
positivity in malignant squamous component (DAB, 200X). B; Strong
positivity of the malignant ductal component for CK19 (DAB, 100X).
Figure 7 CK18 Immunohistochemical stain in MBC. Strong
positivity of the epithelial component for CK18 (DAB, 100X).
Figure 8 Calretinin immunohistochemical staining in MBC.
A: Strong positive cytoplasmic staining in glandular component
(DAB,100X). B: Strong positive cytoplasmic staining in squamous cell
component (DAB,200X). C: Strong positive cytoplasmic staining in
spindle cell component (DAB,100X).
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ological and immunohistochemical profile by our group.
Eighty six percent of our patients were below the age of
Figure 9 PLAP immunohistochemical stain. Diffuse positivity in
multinucleated giant cells for PLAP antibodies (DAB, 200x).
Table 5 Metaplastic carcinoma of breast:
immunohistochemical features
Case NO antibody 1 2 3 4 5 6 7
Calretinin + + + + + + -
Ki-67 1% 3% 2% 30% 1% 4% 1%
P53 + + - + - - -
B-HCG + + + N/P N/P N/P N/P
PLAP + + + N/P N/P N/P N/P
N/P: is not performed.
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in contrast to the Western series [18-21] that reported
MBC in women older than 50 years of age. However,
this range is with accordance with the age range of
breast cancer in Saudi Arabia [22].
Three of our MBC cases (43%) were composed of
highly atypical malignant epithelial and/or mesenchymal
component mixed with scattered multinucleated giant cells
similar morphologically to syncytiotrophoblasts, indicating
choriocarcinomatous differentiation. This differentiation
was evident by immunohistochemical positivity of these
multinucleated syncytiotrophoblast-like giant cells to
β-HCG and PLAP. Interestingly; these cases presented
in a young age group (less than 30 years of age) and
showed relation to pregnancy and preceding abortionFigure 10 β-HCG immunohistochemical stain. Diffuse positivity
for β-HCG antibodies in giant cells (DAB, 400x).in contrast to Mohammadi’s et al. study [23] which
described choriocarcinomatous differentiation in MBC
occurring in perimenopausal and postmenopausal females
except for 2 cases that presented in 31 and 38-year old
pregnant women. Previous studies [23,24] reported that
MBC associated with syncytial cells behaved aggressively
as they presented with advanced stage as well as lymph
node and distant metastasis.
The differential of MBC include wide range of patho-
logical diagnosis, including lobular carcinoma, Pleomorphic
carcinoma and other rare sarcoma such as angiosarcoma.
E-cadherin is a very useful stain in the classification of
breast carcinomas with mixed pattern [14]. Also a rare
entity that was recognized by the World Health Organ-
ization (WHO) classification of tumours of the breast
adopts the terminology of Pleomorphic carcinoma(PC)
should be included in the differential diagnosis. PC is a
very rare variant of high-grade invasive carcinoma of no
special type, characterized by proliferation of pleomorphic
and bizarre giant cells comprising >50% of the tumour cells
in a background of adenocarcinoma or adenocarcinoma
with spindle and squamous differentiation. Yamada S. et al.
reported a rare case of pleomorphic carcinoma (PC) of
breast with cystic changes and presented with a large size
breast tumour. The authors have confirmed that PC is a
unique entity with a significantly poor outcome [25].
Three of our cases are young age group and show
spindle cell proliferation. In this category one has to
think about the differential diagnosis of rare sarcoma.
Bennani et al. report a case of primary angiosarcoma of
the breast that was presented in a 33 years old lady that
exhibit areas of spindle cell proliferation , papillary forma-
tion and prominent vasculature. Immunohistochemical
stains for vascular markers were positive while epithelial
markers are negative. Angiosarcoma of the breast has a
very poor prognosis [26].
In the present study, we tried to categorize our MBC
under the four major molecular subtypes of breast cancer:
luminal, basal-like (triple negative), normal breast-like
and HER2. All the cases of MBC were found to be triple
negative breast carcinomas (TNBC) since none of them
exhibited positivity to ER, PR or HER2. Previous reports
concluded that MBC rarely shows nuclear reactivity for
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[19,27]. The rate of HER2 over-expression is variable
between the studies with rate ranging from 4 to 19.6%
[11] and up to 72% in another study [27]. However, other
studies described that the majority of MBC exhibit triple-
negative features ranging from 77% to 96% [19]. Using
digital image analysis (DA) tool in breast pathology brings
an accurate and high-throughput manner to evaluate IHC
in comparison to the traditional evaluation performed by
a pathologist. Laurinavicius A. et al. looked at the variation
of the intensity of HER2 membranous staining by IHC
and the percentage of cells with complete membranous
staining in the consecutive tissue in 91 sections of 4
different breast cancer cases. They found digital images
of the 2+ serial sections arranged consecutively on
computer monitor revealed staining intensity variation,
in particular, increased intensity that was missed by
conventional microscope review but detected by the
DA. To explore possible “long-term” drifts of the IHC
sensitivity [28].
In addition six out of our seven cases revealed positive
immunoreactivity to at least one of myoepithelial/basal
cell markers; EGFR, CK5/6, P63, SMA and S100. P63
was positive in 2 squamous cell carcinoma cases while
S100 was noted in only one case.
Previous reports [29-33], included MBCs among the
spectrum of basal-like breast carcinomas, since they
usually display a basal/myoepithelial molecular make-up,
basal-like immunophenotype, triple negativity and often
show expression of EGFR, CK14 and CK5/6. They showed
highest percentage of myoepithelial/basal markers (CK5/6,
CK14 and smooth muscle actin) expression in the spindle
cells of MBC. Dunne et al. reported at least focal staining
for SMA in the spindle cell areas along with the expres-
sion of basal cell cytokeratin 14 [34]. Wang et al. [30]
reported strong association between CK5/6 and CK14
expression and MBC with better sensitivity of CK5/6.
Koker and kleer [31] had reported expression of p63 in all
10 spindle cell metaplastic carcinoma examined compared
with only 1 of 174 (0.6%) of other breast carcinomas. Five
of our cases (71%), the three carcinosarcomas and the two
SCCs showed immunohistochemical positivity to EGFR.
Overexpression of EGFR was reported in up to 80% of
cases of MBC, with up to 23-37% of cases confirmed by
in situ hybridization [35,36] EGFR showed association
with squamous or spindle differentiation [35]. Although
MBC has been reported to have high levels of EGFR
over-expression and amplification, they were found to
lack EGFR activating mutations; therefore it is not clear
whether EGFR tyrosine kinase inhibitors are effective for
the treatment of MBC [35,36] Surprisingly, 6 of our cases
expressed positivity for luminal type cytokeratins (CK8,
CK18 and/or CK19) in addition to the basal type cyto-kera-
tin. Our results are comparable to those of Williams et al.[32] who compared the immunoprofile of triple negative
breast carcinomas in Vietnamese population with those
from the United States and concluded that TNBC in both
populations was characterized by the expression of basal
cytokeratins, in combination to luminal cytokeratins (CK8,
CK18, CK19). This interesting finding would support the
hypothesis that MBC arises from a multi-potent stem cell;
however this finding is limited by the small number of cases
in our study [21].
Calretinin was expressed in 5 out 7 cases. Our results
are comparable to those of Taliano who reported high
level of calretinin expression in a significant proportion of
basal-like (54.3%) MBC and he concluded that high-level
calretinin expression is most common in grade 3 tumors
with a basal-like phenotype and is associated with poor
overall survival [37]. Other marker of poor prognosis
is tumor heterogeneity which is one of the biological
characteristic of malignant tumors. In the breast this
feature is not well understood, however Oger M. et al.
looked at this parameter in 368 of their breast cancer
cases and they evaluate many parameters that reflect tumor
heterogeneity. They found that high value of heterogeneity
index is associated with poor prognosis [38].
The reported rate of axillary lymph node metastasis in
cases of MBC is variable in the literature with an incidence
of 15-36%, lower than that of invasive ductal carcinoma
(IDC). Two groups have reported that more than half of
their patients had axillary lymph node metastasis [39]. Four
of our patients (57%) had axillary lymph node dissection
which showed histological evidence of metastasis. However,
this is a limited number of patients to accurately assess the
rate of axillary lymph node involvement.
The prognosis of MBC is still controversial but most
of the studies had demonstrated more aggressive behavior
than IDC [40]. A more recent study by Park et al. [21] had
compared 29 cases of MBC with 4,851 cases of IDC and
had found the survival rates of stage I-III of MBC to be
comparable to those of IDC, although the incidence of
stage IV disease at the diagnosis was higher in MBC.
In our small series, all patients presented with an
advanced stage (stage III) and the majority developed
local recurrence and distant metastasis in a relatively
short period of time.
Conclusion
In conclusion, MBC cases diagnosed at King Abdulaziz
University Hospital presented in a younger age group
in comparison to other series. All of our patients were
in the category of triple negative breast cancers and the
majority showed basal-like type breast cancer immunopro-
file. An interesting finding in this study is the co-expression
of luminal type cytokeratins in the malignant epithelial
component in the majority of our cases. In addition,
calretinin was also expressed in the majority of cases.
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to elucidate the relation between the presence of
syncytiotrophoblast-like giant cells in breast cancer and
pregnancy and to verify the combined expression of
luminal and basal phenotypes in such type of malignancy.
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